Anebulo Pharmaceuticals, Inc.

ANEB

US0345691036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-21 pm EDT			5-day change	1st Jan Change
2.11 ^USD	-1.86%		-7.46%	-12.81%

Feb. 13	Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors

September 27, 2022

On September 28, 2022, Anebulo Pharmaceuticals, Inc. closed the transaction.

Latest news about Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Anebulo Pharmaceuticals Appoints New CEO	23-10-06	MT
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO	23-10-06	CI
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors	23-10-06	CI
Anebulo Pharmaceuticals Appoints Daniel George as Part-Time Finance Chief	23-09-29	MT
Anebulo Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	23-09-29	CI
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer	23-09-29	CI
Maxim Starts Anebulo Pharmaceuticals at Buy With $6 Price Target	23-09-21	MT
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	23-09-20	CI
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer	23-09-18	MT
HC Wainwright Initiates Anebulo Pharmaceuticals With Buy Rating, Price Target is $6	23-09-18	MT
Anebulo Pharmaceuticals, Inc. Announces Resignation of Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer	23-09-05	CI
Anebulo Pharmaceuticals, Inc. Announces Sandra A. Gardiner Resigns as Acting Chief Financial Officer	23-09-05	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11	CI
Anebulo Pharmaceuticals Reports Positive Data from Trial of Cannabinoid Intoxication Treatment; Shares Jump	23-03-28	MT
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of Aneb-001 as A Treatment for Acute Cannabinoid Intoxication	23-03-28	CI
Anebulo Pharmaceuticals Appoints Sandra Gardiner as Acting Chief Financial Officer	23-03-08	MT
Anebulo Pharmaceuticals, Inc. Appoints Sandra Gardiner as Acting Chief Financial Officer	23-03-08	CI
Benchmark Adjusts Anebulo Pharmaceuticals' Price Target to $8 From $10, Keeps Speculative Buy Rating	23-02-14	MT
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-10	CI
Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication	23-01-09	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10	CI
Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director	22-10-28	CI
Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors	22-09-27	CI

Chart Anebulo Pharmaceuticals, Inc.

Duration

Period

More charts

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Companyâs lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.15 USD

Average target price

6 USD

Spread / Average Target

+179.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANEBULO PHARMACEUTICALS, INC.	-12.81%	55.76M
MODERNA, INC.	+44.48%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-0.86%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+29.40%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B

Other Biotechnology & Medical Research